BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 27002325)

  • 1. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
    Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I
    Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Endo S; Kurokawa Y; Gamoh M; Kimura Y; Matsuyama J; Taniguchi H; Takeno A; Kawabata R; Kawada J; Masuzawa T; Yamamoto K; Kobayashi K; Sakai D; Shimokawa T; Satoh T
    Anticancer Res; 2019 Feb; 39(2):1059-1065. PubMed ID: 30711995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
    Kurokawa Y; Sugimoto N; Miwa H; Tsuda M; Nishina S; Okuda H; Imamura H; Gamoh M; Sakai D; Shimokawa T; Komatsu Y; Doki Y; Tsujinaka T; Furukawa H
    Br J Cancer; 2014 Mar; 110(5):1163-8. PubMed ID: 24473399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
    Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
    Chua C; Tan IB; Yamada Y; Rha SY; Yong WP; Ong WS; Tham CK; Ng M; Tai DW; Iwasa S; Lim HY; Choo SP
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):397-408. PubMed ID: 26099969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
    Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
    Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
    Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
    Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
    Mori Y; Kataoka H; Ebi M; Adachi K; Yamaguchi Y; Hayashi N; Hirata Y; Sobue S; Ishihara R; Suzuki Y; Mizushima T; Inoue Y; Hasegawa I; Ono S; Hirano A; Kimura Y; Seno K; Ozeki K; Shimura T; Kubota E
    J Gastrointest Cancer; 2022 Dec; 53(4):930-938. PubMed ID: 34550548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
    Uchima Y; Kosaka K; Kimura K; Okita Y; Sim JK; Aomatsu N; Hirata K; Lee WH; Lee T; Nishii T; Tei S; Takeuchi K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
    Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
    Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
    Okita A; Imai H; Takahashi M; Takahashi H; Umegaki S; Kawamura Y; Hiraide S; Ouchi K; Sato Y; Okada Y; Komine K; Saijo K; Takahashi S; Takahashi M; Shirota H; Ohori H; Gamoh M; Ishioka C
    Tohoku J Exp Med; 2018 Jun; 245(2):123-129. PubMed ID: 29937450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
    BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of S-1 plus oxaliplatin 130 mg/m
    Kashiwada T; Shinozaki K; Ueno S; Kawanaka H; Uno F; Okita Y; Fukahori M; Matsushita H; Emi Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Maehara Y; Mori M; Baba E;
    Int J Clin Oncol; 2021 Feb; 26(2):345-354. PubMed ID: 33085058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.
    Kim YS; Sym SJ; Baek MY; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1267-72. PubMed ID: 26482716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.